Video

Dr. Hamilton on Tests to Identify HER2-Low and HER2+ Breast Cancer

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Though immunohistochemistry (IHC) has traditionally been used to identify patients with HER2-positive breast cancer, IHC has not routinely been utilized to pinpoint patients with HER2-low disease, Hamilton says. With HER2-low breast cancer now considered a separate subgroup, IHC scores of 1+ and 2+ are now actionable, Hamilton continues, adding that since IHC was not initially designed to distinguish between 0 and 1+, there may be a need to refine how HER2 testing is conducted. It is important to educate pathologists and refine testing with this new knowledge of HER2-low patients, Hamilton explains.

By being able to better define and identify patients with HER2-low breast cancer, other antibody-drug conjugates and bispecific antibodies that have produced positive data in HER2-positive breast cancer can be explored in the HER2-low population, Hamilton concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity